Contact Us
Drug Search Results
More Filters [+]

Navamepent

Alternative Names: navamepent, rx-10045
Latest Update: 2019-02-20
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: RvE1 Antagonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Topical,Ophthalmic

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: C.T. Development America
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Navamepent

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Inflammation|Cataract|Conjunctivitis, Allergic|Dry Eye Syndromes|Dry Eye Disease|Keratoconjunctivitis Sicca

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
ATR-45-1401

P2

Completed

Cataract|Inflammation

2015-09-01

CTD1201

P2

Completed

Dry Eye Syndromes|Dry Eye Disease|Keratoconjunctivitis Sicca

2012-11-01

CTD1202

P2

Completed

Conjunctivitis, Allergic

2012-08-01

NCT00799552

P2

Completed

Keratoconjunctivitis Sicca|Dry Eye Syndromes

2009-05-01

Recent News Events

Date

Type

Title

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions